Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction
- PMID: 33437274
- PMCID: PMC7794116
- DOI: 10.12669/pjms.37.1.2950
Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction
Abstract
Objectives: To investigate the effects of etibatide combined with emergency percutaneous coronary intervention (PCI) on blood perfusion and cardiac function in acute myocardial infarction (AMI) patients.
Methods: This was a prospective, randomized, controlled study. From November 2015 to June 2019, 196 patients with ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI admitted to Baoding First Central Hospital were enrolled. The 196 STEMI patients were randomly divided into experimental group and control group. In the experimental group, STEMI patients were treated with emergency PCI + etibatide; while in the control group, only PCI was performed. Observation indexes included: general data, myocardial perfusion and cardiac function indexes and major adverse cardiac events (MACE).
Results: There was no significant difference in general data between the two groups (P > 0.05). The rate of ST-segment resolution (STR) in the experimental group was better than that in the control group (P < 0.05). In myocardial contrast echocardiography (MCE), higher peak intensity (PI) and shorter time-to-peak (TP) were observed in the experimental group compared with the control group (P < 0.05). The platelet aggregation rate was compared between the two group at the time points of before PCI, after PCI and two hour after drug withdrawal, and there was no significant change in the platelet aggregation rate of the control group between different time points (before PCI, after PCI and two hour after drug withdrawal); while the platelet aggregation rate of the experimental group was significantly lower after PCI and two hour after drug withdrawal than that before PCI (P < 0.05), and an obviously decreased platelet aggregation rate was found in the experimental group(P < 0.05). After three months of follow-up, there was one case of MACE in the experimental group and 1 case of MACE in the control group, without any difference in the incidence of MACE between the two groups (P > 0.05).
Conclusion: Etibatide combined with emergency PCI could improve myocardial reperfusion and cardiac function in patients with acute STEMI without increasing the incidence of MACE.
Keywords: Acute myocardial infarction; Cardiac function; Etibatide; Myocardial contrast echocardiography.
Copyright: © Pakistan Journal of Medical Sciences.
Conflict of interest statement
Declaration of conflicting interest: None.
Similar articles
-
[Efficacy comparison of primary percutaneous coronary intervention by drug-coated balloon angioplasty or drug-eluting stenting in acute myocardial infarction patients with de novo coronary lesions].Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):600-607. doi: 10.3760/cma.j.cn112148-20200327-00254. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 32842271 Chinese.
-
Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Coron Artery Dis. 2008 Jun;19(4):271-7. doi: 10.1097/MCA.0b013e3282f487e0. Coron Artery Dis. 2008. PMID: 18480672 Clinical Trial.
-
Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study.BMC Cardiovasc Disord. 2020 Jun 26;20(1):308. doi: 10.1186/s12872-020-01584-0. BMC Cardiovasc Disord. 2020. PMID: 32590944 Free PMC article. Clinical Trial.
-
ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: a meta-analysis.Clin Res Cardiol. 2010 Jan;99(1):1-11. doi: 10.1007/s00392-009-0068-3. Epub 2009 Aug 29. Clin Res Cardiol. 2010. PMID: 19727894 Review.
-
Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction.Catheter Cardiovasc Interv. 2016 Jun;87(7):1203-10. doi: 10.1002/ccd.26352. Epub 2015 Dec 23. Catheter Cardiovasc Interv. 2016. PMID: 26699698 Review.
Cited by
-
Cardio protective effect of nicorandil in reperfusion injury among patients undergoing primary percutaneous coronary intervention.Pak J Med Sci. 2023 Jan-Feb;39(1):177-181. doi: 10.12669/pjms.39.1.6034. Pak J Med Sci. 2023. PMID: 36694786 Free PMC article.
-
Value of Cardiac Troponin, Myoglobin Combined with Heart-type Fatty Acid-binding Protein Detection in Diagnosis of Early Acute Myocardial Infarction.Pak J Med Sci. 2023 Nov-Dec;39(6):1690-1694. doi: 10.12669/pjms.39.6.7101. Pak J Med Sci. 2023. PMID: 37936785 Free PMC article.
-
Efficacy of sacubitril/valsartan combined with dapagliflozin in treating patients with heart failure and diabetes after an acute myocardial infarction.Pak J Med Sci. 2024 Dec;40(11):2464-2469. doi: 10.12669/pjms.40.11.8972. Pak J Med Sci. 2024. PMID: 39634890 Free PMC article.
-
Risk factors for major cardiovascular adverse events and the effects of sacubitril/valsartan in patients with acute myocardial infarction after Percutaneous Coronary Intervention.Pak J Med Sci. 2025 Jun;41(6):1592-1597. doi: 10.12669/pjms.41.6.10819. Pak J Med Sci. 2025. PMID: 40621510 Free PMC article.
References
-
- Lev EI, Kornowski R, Teplisky I, Hasdai D, Rechavia E, Shor N, et al. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction. Int J Cardiovasc Intervent. 2005;7(1):41–45. doi:10.1080/14628840510011180. - PubMed
-
- O'Shea C, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. J Invasive Cardiol. 1999;11(8):494–499. - PubMed
-
- Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ, et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis. 2000;9(1):5–12. doi:10.1023/a:101⇊123272. - PubMed
-
- O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention:a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54(8):678–685. doi:10.1016/j.jacc.2009.05.025. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous